Furthermore, ESR2 was identified as the transcriptional target of TFAP2A by bioinformatics analysis and ChIP, and the combination of the ESR2 inhibitor PHTPP and osimertinib had a synergistic effect on NSCLC with a high level of TFAP2A. The gene discussed is TFAP2A; the disease is non-small cell lung carcinoma.